Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Sera Prognostics, Inc. SERA
$3.41
-$0.08 (-2.46%)
На 18:04, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
109047428.00000000
-
week52high
4.25
-
week52low
1.10
-
Revenue
268000
-
P/E TTM
-2
-
Beta
0.00000000
-
EPS
-1.43000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 ноя 2022 г. в 22:00
Описание компании
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Berenberg | Buy | 27 апр 2022 г. | |
| Citigroup | Neutral | Buy | 30 мар 2022 г. |
| Oppenheimer | Outperform | 19 ноя 2021 г. | |
| William Blair | Outperform | 09 авг 2021 г. | |
| Cowen & Co. | Outperform | 09 авг 2021 г. | |
| Berenberg | Buy | 14 сент 2022 г. | |
| Oppenheimer | Outperform | Outperform | 29 авг 2022 г. |
| Citigroup | Neutral | Neutral | 10 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Boniface John J. | D | 0 | 844 | 08 сент 2022 г. |
| Boniface John J. | A | 47354 | 844 | 08 сент 2022 г. |
| Boniface John J. | D | 844 | 1000 | 27 июл 2022 г. |
| Boniface John J. | D | 46510 | 1000 | 27 июл 2022 г. |
| Boniface John J. | A | 47510 | 1000 | 27 июл 2022 г. |
| Boniface John J. | D | 46510 | 2725 | 26 июл 2022 г. |
| Boniface John J. | D | 49235 | 2725 | 19 июл 2022 г. |
| Blue Ox Healthcare Partners, LLC | D | 46744 | 1157764 | 18 июл 2022 г. |
| Blue Ox Healthcare Partners, LLC | D | 77420 | 997627 | 18 июл 2022 г. |
| Blue Ox Healthcare Partners, LLC | D | 132501 | 1383094 | 18 июл 2022 г. |
Новостная лента
Sera Prognostics, Inc. (SERA) Q3 2022 Earnings Call Transcript
Seeking Alpha
13 ноя 2022 г. в 04:56
Sera Prognostics, Inc. (NASDAQ:SERA ) Q3 2022 Earnings Conference Call November 9, 2022 5:00 PM ET Company Participants Peter DeNardo - CapComm Partners, IR Greg Critchfield - President and CEO Jay Moyes - CFO Conference Call Participants Patrick Donnelly - Citi Andrew Brackmann - William Blair Tom Stevens - Cowen Operator Good afternoon, and welcome to the Sera Prognostics conference call to review Third Quarter Fiscal Year 2022 results. At this time, all participants are in a listen-only mode.
Sera Prognostics, Inc. (SERA) Reports Q3 Loss, Tops Revenue Estimates
Zacks Investment Research
09 ноя 2022 г. в 19:34
Sera Prognostics, Inc. (SERA) delivered earnings and revenue surprises of 12.50% and 2.35%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Sera Prognostics, Inc. (SERA) CEO Greg Critchfield on Q2 2022 Results - Earnings Call Transcript
Seeking Alpha
10 авг 2022 г. в 19:56
Sera Prognostics, Inc. (NASDAQ:SERA ) Q2 2022 Earnings Conference Call August 10, 2022 5:00 PM ET Company Participants Peter DeNardo - CapComm Partners Greg Critchfield - Chairman, President & Chief Executive Officer Jay Moyes - Chief Financial Officer Conference Call Participants Dustin Scaringe - William Blair Dan Brennan - Cowen Operator Good afternoon and welcome to the Sera Prognostics' Conference Call to review Second Quarter Fiscal Year 2022 Results. At this time, all participants are in a listen-only mode.
Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Lags Revenue Estimates
Zacks Investment Research
10 авг 2022 г. в 19:33
Sera Prognostics, Inc. (SERA) delivered earnings and revenue surprises of 7.50% and 22%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
A Negative EV Opportunity - Sera Prognostics Has A Chance To Become Standard Of Care In Preterm Birth Risk Screening
Seeking Alpha
10 авг 2022 г. в 10:00
SERA sells PreTRM®, a CLIA-lab based assay to determine the risk of a woman having a pre-term birth – a birth prior to 37 weeks of gestation. After IPO'ing in July 2021 at $16, the Company has since lost over 80% of its value and trades at 50% of its cash and marketable securities.